Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 2/2010

Open Access 01-06-2010 | Review

Targeted therapies in renal cell cancer: recent developments in imaging

Authors: Astrid A. M. van der Veldt, Martijn R. Meijerink, Alfons J. M. van den Eertwegh, Epie Boven

Published in: Targeted Oncology | Issue 2/2010

Login to get access

Abstract

Targeted therapy has significantly improved the perspectives of patients with metastatic renal cell cancer (mRCC). Frequently, these new molecules cause disease stabilization rather than substantial tumor regression. As treatment options expand with the growing number of targeted agents, there is an increasing need for surrogate markers to early assess tumor response. Here, we review the currently available imaging techniques and response evaluation criteria for the assessment of tumor response in mRCC patients. For computed tomography (CT), different criteria are discussed including the Response Evaluation Criteria in Solid Tumors (RECIST), the Choi criteria, the modified Choi criteria, and the size and attenuation CT (SACT) criteria. Functional imaging modalities are discussed, such as dynamic contrast-enhanced CT (DCE-CT), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), dynamic contrast-enhanced ultrasonography (DCE-US), and positron emission tomography (PET).
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef
2.
Pantuck AJ, Zisman A, Belldegrun AS (2001) The changing natural history of renal cell carcinoma. J Urol 166:1611–1623PubMedCrossRef
3.
Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601–5608PubMedCrossRef
4.
Brugarolas J (2007) Renal-cell carcinoma–molecular pathways and therapies. N Engl J Med 356:185–187PubMedCrossRef
5.
6.
Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28:2144–2150PubMedCrossRef
7.
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134PubMedCrossRef
8.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef
9.
Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462–4468PubMedCrossRef
10.
Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975–984PubMedCrossRef
11.
Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068PubMedCrossRef
12.
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111PubMedCrossRef
13.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590PubMedCrossRef
14.
Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin J (2003) TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4:147–158PubMedCrossRef
15.
Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT (2002) Regulation of hypoxia-inducible factor 1{alpha} expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004–7014PubMedCrossRef
16.
Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594–601PubMedCrossRef
17.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IGH, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, the Global ARCC (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRef
18.
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456PubMedCrossRef
19.
Horger M, Lauer U, Schraml C, Berg C, Koppenhofer U, Claussen C, Gregor M, Bitzer M (2009) Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 9:208PubMedCrossRef
20.
Rodriguez Faba O, Breda A, Rosales A, Palou J, Algaba F, Maroto Rey P, Villavicencio H (2010) Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma. Eur Urol: in press
21.
Van der Veldt AA, Meijerink MR, Van den Eertwegh AJ, Bex A, De Gast G, Haanen JB, Boven E (2008) Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 14:2431–2436PubMedCrossRef
22.
Van der Veldt AA, Meijerink MR, Van den Eertwegh AJ, Haanen JB, Boven E (2010) Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 102:803–809PubMedCrossRef
23.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef
24.
Van Cruijsen H, Van der Veldt AA, Hoekman K (2009) Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions. Front Biosci 14:2248–2268PubMedCrossRef
25.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRef
26.
Thiam R, Fournier LS, Trinquart L, Medioni J, Chatellier G, Balvay D, Escudier B, Dromain C, Cuenod CA, Oudard S (2010) Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol 21:936–941PubMedCrossRef
27.
Jinzaki M, Tanimoto A, Mukai M, Ikeda E, Kobayashi S, Yuasa Y, Narimatsu Y, Murai M (2000) Double-phase helical CT of small renal parenchymal neoplasms: correlation with pathologic findings and tumor angiogenesis. J Comput Assist Tomogr 24:835–842PubMedCrossRef
28.
Miles KA (1999) Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur J Radiol 30:198–205PubMedCrossRef
29.
Miles KA, Charnsangavej C, Lee FT, Fishman EK, Horton K, Lee TY (2000) Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 7:840–850PubMedCrossRef
30.
Han KS, Jung DC, Choi HJ, Jeong MS, Cho KS, Joung JY, Seo HK, Lee KH, Chung J (2010) Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer 116:2332–2342PubMed
31.
Baccala A Jr, Hedgepeth R, Kaouk J, Magi-Galluzzi C, Gilligan T, Fergany A (2007) Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol 14:1095–1097PubMedCrossRef
32.
Smith AD, Lieber ML, Shah SN (2010) Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. Am J Roentgenol 194:157–165CrossRef
33.
Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760–1764PubMedCrossRef
34.
Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759PubMedCrossRef
35.
Maksimovic O, Schraml C, Hartmann JT, Bitzer M, Claussen CD, Pintoffl J, Horger M (2010) Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. Am J Roentgenol 194:5–14CrossRef
36.
Nathan PD, Vinayan A, Stott D, Juttla J, Goh V (2010) CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 9:15–19PubMedCrossRef
37.
Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011–2019PubMedCrossRef
38.
Koukourakis MI, Mavanis I, Kouklakis G, Pitiakoudis M, Minopoulos G, Manolas C, Simopoulos C (2007) Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging. Am J Clin Oncol 30:315–318PubMedCrossRef
39.
Meijerink MR, Van Cruijsen H, Hoekman K, Kater M, Van Schaik C, Van Waesberghe JH, Giaccone G, Manoliu RA (2007) The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol 17:1700–1713PubMedCrossRef
40.
Sahani DV, Kalva SP, Hamberg LM, Hahn PF, Willett CG, Saini S, Mueller PR, Lee TY (2005) Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 234:785–792PubMedCrossRef
41.
Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV (2008) Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 13:120–125PubMedCrossRef
42.
Wang JH, Min PQ, Wang PJ, Cheng WX, Zhang XH, Wang Y, Zhao XH, Mao XQ (2006) Dynamic CT evaluation of tumor vascularity in renal cell carcinoma. AJR Am J Roentgenol 186:1423–1430PubMedCrossRef
43.
Hylton N (2006) Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 24:3293–3298PubMedCrossRef
44.
O’Connor JP, Jackson A, Parker GJ, Jayson GC (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96:189–195PubMedCrossRef
45.
Jackson A, O'Connor JPB, Parker GJM, Jayson GC (2007) Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 13:3449–3459PubMedCrossRef
46.
Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJS (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21:2831–2842PubMedCrossRef
47.
Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT Jr, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS (2005) Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 23:5464–5473PubMedCrossRef
48.
Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxius S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955–3964PubMedCrossRef
49.
Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B, Schnall MD, O'Dwyer PJ (2008) Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 7:496–501PubMed
50.
Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM (2008) Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26:4572–4578PubMedCrossRef
51.
Hillman GG, Singh-Gupta V, Zhang H, Al Bashir AK, Katkuri Y, Li M, Yunker CK, Patel AD, Abrams J, Haacke EM (2009) Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors. Neoplasia 11:910–920PubMed
52.
Rosen MA, Schnall MD (2007) Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 13:770s–776sPubMedCrossRef
53.
De Bazelaire C, Rofsky NM, Duhamel G, Michaelson MD, George D, Alsop DC (2005) Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma1. Acad Radiol 12:347–357PubMedCrossRef
54.
Schor-Bardach R, Alsop DC, Pedrosa I, Solazzo SA, Wang X, Marquis RP, Atkins MB, Regan M, Signoretti S, Lenkinski RE, Goldberg SN (2009) Does arterial spin-labeling MR imaging–measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology 251:731–742PubMedCrossRef
55.
De Bazelaire C, Alsop DC, George D, Pedrosa I, Wang Y, Michaelson MD, Rofsky NM (2008) Magnetic resonance imaging–measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 14:5548–5554PubMedCrossRef
56.
Boss A, Martirosian P, Schraml C, Clasen S, Fenchel M, Anastasiadis A, Claussen CD, Pereira PL, Schick F (2006) Morphological, contrast-enhanced and spin labeling perfusion imaging for monitoring of relapse after RF ablation of renal cell carcinomas. Eur Radiol 16:1226–1236PubMedCrossRef
57.
Taouli B, Thakur RK, Mannelli L, Babb JS, Kim S, Hecht EM, Lee VS, Israel GM (2009) Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology 251:398–407PubMedCrossRef
58.
Harry VN, Semple SI, Parkin DE, Gilbert FJ (2010) Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol 11:92–102PubMedCrossRef
59.
Mardor Y, Pfeffer R, Spiegelmann R, Roth Y, Maier SE, Nissim O, Berger R, Glicksman A, Baram J, Orenstein A, Cohen JS, Tichler T (2003) Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 21:1094–1100PubMedCrossRef
60.
Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, Tsien C, Mukherji S, Quint DJ, Gebarski SS, Robertson PL, Junck LR, Rehemtulla A, Ross BD (2005) Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Nat Acad Sci USA 102:5524–5529PubMedCrossRef
61.
Dzik-Jurasz A, Domenig C, George M, Wolber J, Padhani A, Brown G, Doran S (2002) Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360:307–308PubMedCrossRef
62.
Lee KC, Bradley DA, Hussain M, Meyer CR, Chenevert TL, Jacobson JA, Johnson TD, Galban CJ, Rehemtulla A, Pienta KJ, Ross BD (2007) A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 9:1003–1011PubMedCrossRef
63.
Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, Geschwind JF (2006) The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 17:505–512PubMedCrossRef
64.
Paudyal B, Paudyal P, Tsushima Y, Oriuchi N, Amanuma M, Miyazaki M, Taketomi-Takahashi A, Nakazato Y, Endo K (2010) The role of the ADC value in the characterisation of renal carcinoma by diffusion-weighted MRI. Br J Radiol 83:336–343PubMedCrossRef
65.
Pedrosa I, Alsop DC, Rofsky NM (2009) Magnetic resonance imaging as a biomarker in renal cell carcinoma. Cancer 115:2334–2345PubMedCrossRef
66.
Sandrasegaran K, Sundaram CP, Ramaswamy R, Akisik FM, Rydberg MP, Lin C, Aisen AM (2010) Usefulness of diffusion-weighted imaging in the evaluation of renal masses. AJR Am J Roentgenol 194:438–445PubMedCrossRef
67.
Squillaci E, Manenti G, Cova M, Di RM, Miano R, Palmieri G, Simonetti G (2004) Correlation of diffusion-weighted MR imaging with cellularity of renal tumours. Anticancer Res 24:4175–4179PubMed
68.
Squillaci E, Manenti G, Di SF, Miano R, Strigari L, Simonetti G (2004) Diffusion-weighted MR imaging in the evaluation of renal tumours. J Exp Clin Cancer Res 23:39–45PubMed
69.
Byun WM, Shin SO, Chang Y, Lee SJ, Finsterbusch J, Frahm J (2002) Diffusion-weighted MR imaging of metastatic disease of the spine: assessment of response to therapy. AJNR Am J Neuroradiol 23:906–912PubMed
70.
Lassau N, Chami L, Benatsou B, Peronneau P, Roche A (2007) Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment. Eur Radiol 17(Suppl 6):F89–F98PubMed
71.
Kabakci N, Igci E, Secil M, Yorukoglu K, Mungan U, Celebi I, Kirkali Z (2005) Echo contrast-enhanced power doppler ultrasonography for assessment of angiogenesis in renal cell carcinoma. J Ultrasound Med 24:747–753PubMed
72.
Lassau N, Chebil M, Chami L, Bidault S, Girard E, Roche A (2010) Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment. Target Oncol 5:53–38PubMedCrossRef
73.
Lassau N, Koscielny S, Opolon P, De Baere T, Peronneau P, Leclere J, Roche A (2001) Evaluation of contrast-enhanced color doppler ultrasound for the quantification of angiogenesis in vivo. Invest Radiol 36:50–55PubMedCrossRef
74.
Krix M, Kiessling F, Farhan N, Schmidt K, Hoffend J, Delorme S (2003) A multivessel model describing replenishment kinetics of ultrasound contrast agent for quantification of tissue perfusion. Ultrasound Med Biol 29:1421–1430PubMedCrossRef
75.
Lamuraglia M, Escudier B, Chami L, Schwartz B, Leclere J, Roche A, Lassau N (2006) To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 42:2472–2479PubMedCrossRef
76.
Lassau N, Koscielny S, Albiges L, Chami L, Benatsou B, Chebil M, Roche A, Escudier BJ (2010) Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 16:1216–1225PubMedCrossRef
77.
Lassau N, Lamuraglia M, Chami L, Leclere J, Bonvalot S, Terrier P, Roche A, Le Cesne A (2006) Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. Am J Roentgenol 187:1267–1273CrossRef
78.
Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel E, Armand JP, Robert C (2007) Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 13:1801–1809PubMedCrossRef
79.
Battistella M, Mateus C, Lassau N, Chami L, Boukoucha M, Duvillard P, Cribier B, Robert C (2010) Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma. J Eur Acad Dermatol Venereol 24:199–203PubMedCrossRef
80.
Rouffiac V, Bouquet C, Lassau N, Opolon P, Koscielny S, Peronneau P, Perricaudet M, Roche A (2004) Validation of a new method for quantifying in vivo murine tumor necrosis by sonography. Invest Radiol 39:350–356PubMedCrossRef
81.
Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2:683–693PubMedCrossRef
82.
Nakatani K, Nakamoto Y, Saga T, Higashi T, Togashi K (2010) The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Eur J Radiol: in press
83.
Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F, Sobrio F, Bouvard G, Agostini D (2003) Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 30:1236–1245PubMedCrossRef
84.
Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, Mekhail TM, Olencki TE, Elson P, Bukowski RM (2003) F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 21:3995–4000PubMedCrossRef
85.
Park JW, Jo MK, Lee HM (2009) Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int 103:615–619PubMedCrossRef
86.
Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N, Yasuda S (2002) Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 9:15–18PubMedCrossRef
87.
Ramdave S, Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HT, Macgregor D, Scott AM (2001) Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 166:825–830PubMedCrossRef
88.
Brouwers AH, Dorr U, Lang O, Boerman OC, Oyen WJ, Steffens MG, Oosterwijk E, Mergenthaler HG, Bihl H, Corstens FH (2002) 131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nucl Med Commun 23:229–236PubMedCrossRef
89.
Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R (2000) A combined PET/CT scanner for clinical oncology. J Nucl Med 41:1369–1379PubMed
90.
Jennens RR, Rosenthal MA, Lindeman GJ, Michael M (2004) Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome. Urol Oncol 22:193–196PubMed
91.
Lara PN Jr, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR (2003) SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 9:4772–4781PubMed
92.
Lyrdal D, Boijsen M, Suurkula M, Lundstam S, Stierner U (2009) Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun 30:519–524PubMedCrossRef
93.
Vercellino L, Bousquet G, Baillet G, Barre E, Mathieu O, Just PA, Desgrandchamps F, Misset JL, Hindie E, Moretti JL (2009) 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm 24:137–144PubMedCrossRef
94.
Van Oosterom AT, Judson I, Verweij J, Stroobants S, Di Paola ED, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421–1423PubMedCrossRef
95.
Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, Martens M, Van den Borne B, Cole P, Sciot R, Dumez H, Silberman S, Mortelmans L, Van Oosterom A (2003) 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012–2020PubMedCrossRef
96.
Nogova L, Boellaard R, Kobe C, Hoetjes N, Zander T, Gross SH, Dimitrijevic S, Pellas T, Eschner W, Schmidt K, Bangard C, Hayes W, Thomas RK, Dietlein M, Giaccone G, Hoekstra OS, Lammertsma AA, Wolf J (2009) Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. J Nucl Med 50:1815–1819PubMedCrossRef
97.
Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, Guillou L, Elsig V, Stupp R, Delaloye AB, Leyvraz S (2009) Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 27:439–445PubMedCrossRef
98.
Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S–150SPubMedCrossRef
99.
Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37:181–200PubMedCrossRef
100.
Shreve P, Chiao PC, Humes HD, Schwaiger M, Gross MD (1995) Carbon-11-Acetate PET imaging in renal disease. J Nucl Med 36:1595–1601PubMed
101.
Shreve PD, Gross MD (1997) Imaging of the pancreas and related diseases with PET carbon-11-acetate. J Nucl Med 38:1305–1310PubMed
102.
Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, Sadato N, Yamamoto K, Okada K (2002) 11C-Acetate PET imaging of prostate cancer. J Nucl Med 43:181–186PubMed
103.
Maleddu A, Pantaleo MA, Castellucci P, Astorino M, Nanni C, Nannini M, Busato F, Di BM, Farsad M, Lodi F, Boschi S, Fanti S, Biasco G (2009) 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. Tumori 95:382–384PubMed
104.
Anderson H, Yap JT, Wells P, Miller MP, Propper D, Price P, Harris AL (2003) Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer 89:262–267PubMedCrossRef
105.
Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM (2003) Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21:2823–2830PubMedCrossRef
106.
Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL (2002) Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20:3804–3814PubMedCrossRef
107.
De Langen AJ, Van den Boogaart V, Marcus JT, Lubberink M (2008) Use of H2(15)O-PET and DCE-MRI to measure tumor blood flow. Oncologist 13:631–644PubMedCrossRef
108.
Lubberink M, Van der Veldt A, Knaapen P, Harms H, Smit E, Hendrikse H, Lammertsma A (2009) Measurement of tumor and myocardial perfusion using 15O-water and a clinical PET-CT scanner. J Nucl Med Meeting 50(Supplement 2):238
109.
Hoekstra CJ, Stroobants SG, Hoekstra OS, Smit EF, Vansteenkiste JF, Lammertsma AA (2002) Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H215O and positron emission tomography. Clin Cancer Res 8:2109–2115PubMed
110.
Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334–1336PubMedCrossRef
111.
Chen W, Delaloye S, Silverman DHS, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F]fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25:4714–4721PubMedCrossRef
112.
Lawrentschuk NM, Poon AMTM, Scott AMM (2006) Fluorine-18 Fluorothymidine: a new positron emission radioisotope for renal tumors. Clin Nucl Med 31:788–789PubMedCrossRef
113.
Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, Aboagye EO (2009) A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res 69:120–127PubMedCrossRef
114.
Van der Veldt AA, Luurtsema G, Lubberink M, Lammertsma AA, Hendrikse NH (2008) Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance. Curr Pharm Des 14:2914–2931PubMedCrossRef
115.
Nagengast WB, De Vries EG, Hospers GA, Mulder NH, De Jong JR, Hollema H, Brouwers AH, Van Dongen GA, Perk LR, Lub-de Hooge MN (2007) In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 48:1313–1319PubMedCrossRef
116.
Wang JQ, Miller KD, Sledge GW, Zheng QH (2005) Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase. Bioorg Med Chem Lett 15:4380–4384PubMedCrossRef
117.
Nagengast WB, De Korte MA, Oude Munnink TH, Timmer-Bosscha H, Den Dunnen WF, Hollema H, De Jong JR, Jensen MR, Quadt C, Garcia-Echeverria C, Van Dongen GA, Lub-de Hooge MN, Schroder CP, De Vries EG (2010) 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 51:761–767PubMedCrossRef
118.
Bex A, Horenblas S, Meinhardt W, Verra N, De Gast GC (2002) The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol 42:570–574PubMedCrossRef
119.
Bex A, Kerst M, Mallo H, Meinhardt W, Horenblas S, De Gast GC (2006) Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study. Eur Urol 49:76–81PubMedCrossRef
120.
Sella A, Swanson DA, Ro JY, Putnam JB Jr, Amato RJ, Markowitz AB, Logothetis CJ (1993) Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol 149:19–21PubMed
121.
Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655–1659PubMedCrossRef
122.
Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171:1071–1076PubMedCrossRef
123.
Mickisch GH, Garin A, Van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966–970PubMedCrossRef
124.
Biswas S, Kelly J, Eisen T (2009) Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist 14:52–59PubMedCrossRef
125.
Bex A, Van der Veldt AA, Blank C, Van den Eertwegh AJ, Boven E, Horenblas S, Haanen J (2009) Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 27:533–539PubMedCrossRef
126.
Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK (2010) Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 28:1502–1507PubMedCrossRef
127.
Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK (2008) Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 72:864–868PubMedCrossRef
128.
Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC (2009) Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 181:518–523PubMedCrossRef
129.
Bex A, Van der Veldt AA, Blank C, Meijerink MR, Boven E, Haanen JB (2010) Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol 49:520–523PubMedCrossRef
130.
Kunkle DA, Crispen PL, Li T, Uzzo RG (2007) Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol 177:1692–1697PubMedCrossRef
131.
Schwartz LH, Mazumdar M, Wang L, Smith A, Marion S, Panicek DM, Motzer RJ (2003) Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. Cancer 98:1611–1619PubMedCrossRef
132.
Van der Veldt AA, Boven E, Bex A (2009) Re: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. A. A. Thomas, B. I. Rini, B. R. Lane, J. Garcia, R. Dreicer, E. A. Klein, A. C. Novick And S. C. Campbell. J Urol 2009; 181: 518–523. J Urol 182:797–798
133.
Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N (2009) Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27:4076–4081PubMedCrossRef
134.
Cowey CL, Fielding JR, Kimryn Rathmell W (2009) The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. Urology 75:1108–1113PubMedCrossRef
135.
Motzer RJ, Nanus DM, Russo P, Berg WJ (2007) Renal cell carcinoma. Curr Probl Cancer 21:185–232CrossRef
136.
Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M (2009) Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 27:4274–4280PubMedCrossRef
137.
Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, Leighl NB, Shepherd FA, Powers J, Seymour L, Laurie SA (2009) Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 27:404–410PubMedCrossRef
138.
Zolnierek J, Nurzynski P, Langiewicz P, Oborska S, Wasko-Grabowska A, Kuszatal E, Obrocka B, Szczylik C (2010) Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol 136:371–378PubMedCrossRef
139.
Wu HC, Yen RF, Shen YY, Kao CH, Lin CC, Lee CC (2002) Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99 m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report. J Cancer Res Clin Oncol 128:503–506PubMedCrossRef
140.
Bauerle T, Semmler W (2009) Imaging response to systemic therapy for bone metastases. Eur Radiol 19:2495–2507PubMedCrossRef
141.
Schellinger PD, Meinck HM, Thron A (1999) Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 44:275–281PubMedCrossRef
142.
Helgason HH, Mallo HA, Droogendijk H, Haanen J, Van der Veldt AA, Van den Eertwegh AJ, Boven E (2008) Brain metastases in patients with renal cell cancer receiving new targeted treatment. J Clin Oncol 26:152–154PubMedCrossRef
143.
Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP (2007) Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res 27:4255–4257PubMed
144.
Medioni J, Cojocarasu O, Belcaceres JL, Halimi P, Oudard S (2007) Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol 18:1282–1283PubMedCrossRef
145.
Valcamonico F, Ferrari V, Amoroso V, Rangoni G, Simoncini E, Marpicati P, Vassalli L, Grisanti S, Marini G (2009) Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J Neurooncol 91:47–50PubMedCrossRef
146.
Zeng H, Li X, Yao J, Zhu Y, Liu J, Yang Y, Qiang W (2009) Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib. Urol Int 83:482–485PubMedCrossRef
147.
Hill KL Jr, Lipson AC, Sheehan JM (2009) Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. J Neurosurg 111:497–503PubMedCrossRef
148.
Batchelor TT, Sorensen AG, Di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95PubMedCrossRef
149.
Hillman SL, An MW, O'Connell MJ, Goldberg RM, Schaefer P, Buckner JC, Sargent DJ (2009) Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a North Central Cancer Treatment Group Investigation. J Clin Oncol 27:3205–3210PubMedCrossRef
150.
Sica DA (2006) Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 24:1329–1331PubMedCrossRef
151.
Van der Veldt AA, Boven E, Vroling L, Broxterman HJ, Van den Eertwegh AJ, Haanen JG (2009) Sunitinib-induced hemoglobin changes are related to the dosing schedule. J Clin Oncol 27:1339–1340PubMedCrossRef
152.
Azizi M, Chedid A, Oudard S (2008) Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 358:95–97PubMedCrossRef
153.
Van der Veldt AA, De Boer MP, Boven E, Eringa EC, Van den Eertwegh AJ, Van Hinsbergh VW, Smulders YM, Serne EH (2010) Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer Drugs 21:439–446PubMedCrossRef
154.
Van der Veldt AA, Boven E, Helgason HH, Van Wouwe M, Berkhof J, De Gast G, Mallo H, Tillier CN, Van den Eertwegh AJ, Haanen JB (2008) Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 99:259–265PubMedCrossRef
155.
Desar IM, Mulder SF, Stillebroer AB, Van Spronsen DJ, Van der Graaf WT, Mulders PFA, Van Herpen CM (2009) The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol 48:927–931PubMedCrossRef
Metadata
Title
Targeted therapies in renal cell cancer: recent developments in imaging
Authors
Astrid A. M. van der Veldt
Martijn R. Meijerink
Alfons J. M. van den Eertwegh
Epie Boven
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Targeted Oncology / Issue 2/2010
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-010-0146-5

Other articles of this Issue 2/2010

Targeted Oncology 2/2010 Go to the issue

Review

Targeted therapy for locally advanced renal cell carcinoma

Review

Emerging molecular classification in renal cell carcinoma: implications for drug development

Review

Targeted therapies for non-clear renal cell carcinoma

Editorial

Renal cell carcinoma: ten years of significant advances

Review

Targeted therapies for renal cell carcinoma: understanding their impact on survival

Perspectives

Perspectives in drug development for metastatic renal cell cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits